Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in Germany / NCT07111884
Recruiting Observational

GMMG Multiple Myeloma Registry

NCT07111884 · tracked via the Priya Life Science Germany tracker
Sponsor
Prof. Dr. Hartmut Goldschmidt
Phase
Observational
Started
2022-12-08
Last updated
2025-08-08

Condition(s) studied

Multiple Myeloma

Study summary

The goal of this observational study is to collect long-term clinical follow-up data on patients with multiple myeloma who participated in a therapy study of the German-Speaking Myeloma Multicenter Group (GMMG). Target variables of interest are:

Overall survival, progression-free survival and follow-up time.

The relevant registry data will be provided and evaluated together with the therapy study data for scientific research projects.

This allows seamless documentation of patient data from the end of the trial to long-term follow-up.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Previous participation in a a therapy study of the GMMG study group Exclusion Criteria: * patients with organ amyloidosis at time of diagnosis

Primary outcome measure(s)

  • progression free survival — after 5 years, and then through study completion, an average of 1 year

Trial sites (35)

FacilityCityRegionStatus
HELIOS Klinikum, Klinik für Hämatologie, Onkologie und Immunologie Berlin Germany Recruiting
Charité Campus Benjamin Franklin, III. Med. Abt. (Hämatologie/Onkologie) Berlin Germany Recruiting
Klinikum Bielefeld, Klinik für Hämatologie, Onkologie und Palliativmedizin Bielefeld Germany Recruiting
Medizinische Universitätsklinik, Knappschaftskrankenhaus Bochum Germany Recruiting
Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik III, Schwerpunkt Onkologie, Hämatologie und Rheumatologie Bonn Germany Recruiting
Klinikum Chemnitz GmbH, Innere Medizin III Chemnitz Germany Recruiting
Universitätsklinikum Köln, Klinik I - Innere Medizin Cologne Germany Recruiting
Onkologisches Studienzentrum Darmstadt Darmstadt Germany Recruiting
Klinikum Darmstadt, Med. Klinik V, Hämatologie/Onkologie Darmstadt Germany Recruiting
Universitätsklinikum Düsseldorf, Klinik für Hämatologie,Onkologie und Klin. Immunologie Düsseldorf Germany Recruiting
Universitätsklinik Erlangen Erlangen Germany Recruiting
Universitätsklinikum Essen, Klinik für Hämatologie und Stammzelltransplantation Essen Germany Recruiting
Ev. Krankenhaus Essen-Werden gGmbH, Zentrum für Innere Medizin, Klinik für Hämatologie, Onkologie und Stammzelltransplantation Essen Germany Recruiting
Universitätsklinikum Frankfurt, Goethe-Universität Medizinische Klinik II Frankfurt am Main Germany Recruiting
Justus-Liebig-Universität, Medizinische Klinik IV Giessen Germany Recruiting
Kath. Krankenhaus Hagen GmbH, Abt. Hämatologie/Onkologie Hagen Germany Recruiting
Asklepios Klinik Hamburg Altona, II. Med. Klinik Hamburg Germany Recruiting
Onkologische Schwerpunktpraxis Heidelberg Germany Recruiting
University Hospital Heidelberg, Med. Klinik V Heidelberg Germany Recruiting
SLK Kliniken Heilbronn, Med. Klinik III Heilbronn Germany Recruiting
Universitätsklinikum des Saarlandes, Innere Medizin I Homburg Germany Recruiting
Westpfalz-Klinikum GmbH Kaiserslautern Germany Recruiting
Praxisklinik für Hämatologie und Onkologie Koblenz Germany Recruiting
Onkologisches Zentrum, Gemeinschaftspraxis f. Hämatologie u. Onkologie im Caritas KH Lebach Germany Recruiting
Universitätsmedizin der Johannes Gutenberg-Universität Mainz, III. Med. Klinik Mainz Germany Recruiting
III. Medizinische Klinik Hämatologie und Internistische Onkologie Mannheim Germany Recruiting
Mannheimer Onkologie Praxis Mannheim Germany Recruiting
Philipps-Universität Marburg, Hämatologie/Onkologie/Immunologie Marburg Germany Recruiting
Krankenhaus Maria Hilf GmbH, Franziskuskrankenhaus, Med. Klinik I Mönchengladbach Germany Recruiting
Krankenhaus Barmherzige Brüder, Klinik für Onkologie und Hämatologie Regensburg Germany Recruiting
Diakonie-Klinikum Schwäbisch Hall gGmbH, Innere Medizin III Schwäbisch Hall Germany Recruiting
ZAHO-Zentrum für ambulante Hämatologie und Onkologie, Standort Siegburg Siegburg Germany Recruiting
Diakonissen-Stiftungs-Krankenhaus Speyer Speyer Germany Recruiting
Klinikum Mutterhaus der Borromäerinnen gGmbH Trier Germany Recruiting
University Hospital Tübingen, Med. Klinik und Poliklinik, Abt. II Tübingen Germany Recruiting

Other trials for the same condition

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma Recruiting
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma Active, not recruiting
Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL) Active, not recruiting
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM Active, not recruiting
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07111884 on ClinicalTrials.gov ↗ ← All trials in Germany